勘误：食管癌中免疫检查点抑制剂与胸部放疗联合应用的毒性特征：一项荟萃分析和系统评价。
Corrigendum: Toxicity profile of combined immune checkpoint inhibitors and thoracic radiotherapy in esophageal cancer: A meta-analysis and systematic review.
作者信息
Xu Tongzhen, Liu Yunsong, Lu Xiaotong, Liang Jun
机构信息
Department of Radiotherapy Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Radiotherapy Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.
出版信息
Front Immunol. 2023 Apr 11;14:1193710. doi: 10.3389/fimmu.2023.1193710. eCollection 2023.
Abstract
[This corrects the article DOI: 10.3389/fimmu.2022.1039020.].
摘要
[本文更正了文章的数字对象标识符：10.3389/fimmu.2022.1039020。]
相似文献
1
Corrigendum: Toxicity profile of combined immune checkpoint inhibitors and thoracic radiotherapy in esophageal cancer: A meta-analysis and systematic review.勘误：食管癌中免疫检查点抑制剂与胸部放疗联合应用的毒性特征：一项荟萃分析和系统评价。
Front Immunol. 2023 Apr 11;14:1193710. doi: 10.3389/fimmu.2023.1193710. eCollection 2023.
2
Corrigendum: The Significance of Transarterial Chemo(embolization) Combined With Tyrosine Kinase Inhibitors and Immune Check Point Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review.勘误：经动脉化疗（栓塞）联合酪氨酸激酶抑制剂和免疫检查点抑制剂在全身治疗时代对不可切除肝细胞癌的意义：一项系统评价。
Front Immunol. 2022 Jun 7;13:952446. doi: 10.3389/fimmu.2022.952446. eCollection 2022.
3
Corrigendum: The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma.勘误：一线免疫检查点抑制剂治疗肺肉瘤样癌的疗效与安全性分析
Front Immunol. 2023 Sep 6;14:1269596. doi: 10.3389/fimmu.2023.1269596. eCollection 2023.
4
Toxicity Profile of Combining PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy in Non-Small Cell Lung Cancer: A Systematic Review.联合 PD-1/PD-L1 抑制剂和胸部放疗治疗非小细胞肺癌的毒性特征：系统评价。
Front Immunol. 2021 Mar 30;12:627197. doi: 10.3389/fimmu.2021.627197. eCollection 2021.
5
Corrigendum: Peripheral blood lymphocyte subsets predict the efficacy of immune checkpoint inhibitors in non- small cell lung cancer.勘误：外周血淋巴细胞亚群可预测免疫检查点抑制剂在非小细胞肺癌中的疗效。
Front Immunol. 2022 Dec 8;13:1111230. doi: 10.3389/fimmu.2022.1111230. eCollection 2022.
6
Corrigendum: Tumor infiltrating T cell states and checkpoint inhibitor expression in hepatic and pancreatic malignancies.勘误：肝脏和胰腺恶性肿瘤中的肿瘤浸润性T细胞状态及检查点抑制剂表达
Front Immunol. 2023 Mar 23;14:1177713. doi: 10.3389/fimmu.2023.1177713. eCollection 2023.
7
Corrigendum: Alveolar macrophages in lung cancer: opportunities and challenges.勘误：肺癌中的肺泡巨噬细胞：机遇与挑战
Front Immunol. 2023 Nov 6;14:1328927. doi: 10.3389/fimmu.2023.1328927. eCollection 2023.
8
Corrigendum: Immune Responses to Gametocyte Antigens in a Malaria Endemic Population-The African Context: A Systematic Review and Meta-Analysis.勘误：疟疾流行地区人群对配子体抗原的免疫反应——非洲背景：一项系统评价和荟萃分析
Front Immunol. 2020 Mar 23;11:389. doi: 10.3389/fimmu.2020.00389. eCollection 2020.
9
Corrigendum: Innate Immune Cells in the Esophageal Tumor Microenvironment.勘误：食管肿瘤微环境中的固有免疫细胞
Front Immunol. 2021 May 27;12:708705. doi: 10.3389/fimmu.2021.708705. eCollection 2021.
10
Corrigendum: Targeting myeloid checkpoint molecules in combination with antibody therapy: A novel anti-cancer strategy with IgA antibodies?勘误：联合抗体疗法靶向髓系检查点分子：一种使用IgA抗体的新型抗癌策略？
Front Immunol. 2022 Sep 13;13:1017924. doi: 10.3389/fimmu.2022.1017924. eCollection 2022.
Zotero 插件